Therefore, our findings reveal a moonlighting function of GCLM and suggest that targeting the nuclear GCLM–NKRF–NF-κB axis constitutes a selective treatment for attenuating chemoresistance and CRC progression. Here, NKRF is linked to colorectal carcinoma.